Milestones 2003
Enter Phase I clinical Trials for CO-501
Nominate compound from p38 MAP Kinase to GLP-tox by the end of 2003
Potential progress for partnered compound(s)
Continue to meet all collaborator goals
Previous slide
Next slide
Back to first slide
View graphic version